Aelis Farma SA (EPA: AELIS)
France flag France · Delayed Price · Currency is EUR
2.660
-0.020 (-0.75%)
Dec 3, 2024, 3:55 PM CET

Aelis Farma Company Description

Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders.

It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments.

The company was incorporated in 2013 and is headquartered in Bordeaux, France.

Aelis Farma SA
Country France
Founded 2013
Industry Biotechnology
Sector Healthcare
Employees 26
CEO Pier Piazza

Contact Details

Address:
146 rue Lafaurie de Monbadon
Bordeaux, 33 000
France
Phone 33 5 54 54 23 27
Website aelisfarma.com

Stock Details

Ticker Symbol AELIS
Exchange Euronext Paris
Fiscal Year January - December
Reporting Currency EUR
ISIN Number FR0014007ZB4
SIC Code 2836

Key Executives

Name Position
Dr. Pier Vincenzo Piazza M.D., Ph.D. Chief Executive Officer and Director
Marie Line Lefevre Head of Finance
Stephanie Monlezun Chief Operating Officer
Lea Floquet Head of Legal
Arsene Guekam Chief Corporate Development Officer
Sandy Fabre Head of Discovery and IP Leader
Aurelie Boucard Head of Preclinical Development
Helle Mengel Head of Clinical Development
Corinne Chaimbault Head of Pharmaceutical Development